According to the new market research report “Liquid Biopsy Market“ worth USD 2,047.9 Million by 2022, at a CAGR of 23.4%.
Get 133 Market Data Tables and 44 Figures spread through 204 Pages and in-depth TOC on “Liquid Biopsy Market by Cancer Type (Lung, Breast, Colorectal, Prostate), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA), Product (Instruments, Assay Kits), End User (Reference Laboratory) – Global Forecast to 2022”
https://www.marketsandmarkets.com/Market-Reports/liquid-biopsy-market-13966350.html
The key factors driving the growth of this market include increasing prevalence of cancer, increasing preference for noninvasive procedures, initiatives undertaken by government and global health organizations, technological advancement to augment market revenues, rising emphasis on personalized medicine, and availability of funding for liquid biopsy R&D.
Objectives of the Study
- To define, describe, and forecast the global market on the basis of product, clinical application, application, end user, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to four main regions (along with countries), namely, North America, Europe, Asia Pacific, and the Rest of the World
- To profile key players and comprehensively analyze their market shares and core competencies
- To track and analyze competitive developments such as acquisitions, product developments, partnerships, agreements, expansions, and collaborations in the global market
On the basis of product, the liquid biopsy market is broadly segmented into assays kits, instruments, and services. In 2017, the assay kits segment is expected to account for the largest share of this market. The increase in basic research and commercial applications of liquid biopsy, increase in demand for liquid biopsy tests, and the need for reliable and specific assays are expected to drive the market growth.
Based on circulating biomarkers the market is categorized into circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers. In 2017, the circulating tumor cells segment is expected to account for the largest share of the liquid biopsy market. The ability for early assessment of patient prognosis and also providing valuable information to make a clinical decision is driving the growth of the CTC segment in the liquid biopsy market.
By clinical application, the therapy selection segment is expected to account fors the largest market share in 2017
By application, the cancer segment is expected to account for the largest market share in 2017
By end user, the reference laboratories segment is expected to account for the largest market share in 2017
Download Free Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=13966350
North America is expected to account for the largest share of the liquid biopsy market in 2017, followed by Europe. A number of factors such as the easy accessibility and high adoption of advanced diagnostic technologies (such as PCR and NGS) among healthcare professionals, rising prevalence of cancer in the US and Canada, technological advancements in liquid biopsy products, and growing public and private funding to support research activities in the field of liquid biopsy are aiding market growth in the region
Get Sample Pages: https://www.marketsandmarkets.com/requestsample.asp?id=13966350
Market Players
The key players in the global liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDx Health SA (US).
Target Audience:
- Liquid biopsy system manufacturers, suppliers, and distributors
- Research institutes
- Physicians and surgeons
- Healthcare service providers and clinical research organizations
- Market research and consulting firms
Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
newsletter@marketsandmarkets.com
